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Congenital adrenal hyperplasia (CAH) is one of the most frequent autosomal recessive 
diseases in Europe. Treatment is a challenge for pediatric endocrinologists. Important 
parameters to judge the outcome are adult height and menstrual cycle. We report the 
follow-up from birth to adulthood of two Caucasian sisters with salt-wasting CAH due 
to the same mutation, homozygosity c.290-13A>G (I2 splice), in the 21-hydroxylase 
gene. Their adherence to treatment was excellent. Our objective was to distinguish the 
effects of treatment with hydrocortisone (HC) and fludrocortisone (FC) on final height 
(FH) from constitutional factors. The older girl (patient 1), who showed virilized genitalia 
Prader scale III–IV at birth, reached FH within familial target height at 18 years of age. 
Menarche occurred at the age of 15. Her menstrual cycles were always irregular. Total 
pubertal growth was normal (29  cm). She showed a growth pattern consistent with 
constitutional delay. The younger sister (patient 2) was born without masculinization of 
the genitalia after her mother was treated with dexamethasone starting in the fourth 
week of pregnancy. She reached FH at 16 years of age. Her adult height is slightly below 
familial target height. Menarche occurred at the age of 12.5, followed by regular menses. 
Total pubertal growth was normal (21 cm). The average dose of HC from birth to FH was 
16.7 mg/m2 in patient 1 and 16.8 mg/m2 in patient 2. They received FC once a day in 
doses from 0.05 to 0.1 mg. Under such therapy, growth velocity was normal starting 
from the age of 2.5  years with an overall average of +0.2 SD in patient 1 and −0.1 
SD in patient 2, androstenedione levels were always within normal age range. Similarly, 
BMI and blood pressure were always normal, no acne and no hirsutism ever appeared. 
In conclusion, two siblings with the same genetic form of 21-hydroxylase deficiency 
and excellent adherence to medication showed different growth and menstrual cycle 
patterns, rather related to constitutional factors than to underlying CAH. In addition, the 
second patient represents an example of successful in utero glucocorticoid treatment to 
prevent virilization of the external genitalia.
Keywords: adrenal hyperplasia, congenital, adult height, hydrocortisone treatment, constitutional delay, in utero 
dexamethasone
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Congenital adrenal hyperplasia (CAH) is one of the most frequent 
autosomal recessive diseases in central Europe. The reported inci-
dence in Switzerland since the introduction of neonatal screening 
in 1992 is approximately 1:9,500 births.1 The reported worldwide 
incidence is approximately 1:16,000 births (1). Treatment remains 
a challenge for pediatric endocrinologists. The daily production 
rate of cortisol is approximately 8 mg/m2/day. Because of entero-
hepatic circulation, a hydrocortisone (HC) replacement dose of 
at least 10–12 mg/m2/day is required. However, a dose of at least 
15 mg/m2/day is mostly needed to reach ACTH suppression in 
children with CAH. Recent data support the recommendation 
that the daily HC dose should not exceed 17 mg/m2 to optimize 
pubertal growth (2). Over the last three decades, a trend toward 
increased final height (FH) was observed (3), possibly due to a 
progressive reduction of total daily dose of glucocorticoids used.
In CAH, the onset of puberty and pubertal development is 
expected to be normal if glucocorticoid (and mineralocorticoid) 
supplementation is maintained at adequate levels. Menarche and 
menstrual cycle are very sensitive parameters, which are surely 
partly dependent on specific hormonal control of CAH, and also 
show very wide constitutional variability. Of note, polycystic 
ovary syndrome (PCOS) is more frequent in poorly controlled 
patients with CAH (3).
Concerning prenatal prevention of masculinization, antenatal 
treatment with dexamethasone has been recommended in the 
1980s and 1990s (4). More recently, a review of such practice has 
been advocated because of potential adverse maternal–fetal side 
effects (5, 6). Currently, antenatal dexamethasone treatment is 
no longer generally recommended but should be carried out in 
specialized centers following approved protocols (7).
Herein, we describe and analyze retrospectively the growth 
pattern and pubertal development of two siblings with the same 
genetic form of 21-hydroxylase deficiency and excellent adher-
ence to glucocorticoid and mineralocorticoid supplementation 
from birth to adulthood. The aim of this study was to distinguish 
the effects of glucocorticoid treatment on FH from possible 
constitutional factors.
MetHoDs
Both patients were followed up at our clinic, patient 1 from the age 
of 6 months and patient 2 from birth. The diagnosis of CAH was 
based on a virilized genitalia in the first child at birth and prenatal 
genetic diagnosis in the second one. Regular follow-up appoint-
ments took place every 3–6  months at our clinic. Adjustment 
of glucocorticoid dose was made based on auxological data 
(linear growth), skeletal maturity (as assessed by the Greulich 
and Pyle method), and determination of adrenal steroids (total 
17-ketosteroids in 24-h-urine collection in patient 1 until the age 
of 3 years and plasma androstenedione concentrations measured 
at least every 6 months in both patients).
Familial target height was calculated as (maternal + paternal 
height/±13 cm)/2. Total pubertal growth was defined as growth 
from the breast Tanner stage 2 (B2) until reaching FH. Values of 
1 www.neoscreening.ch.
20.3 ± 6.8 were reported to be normal in females (8). Height and 
BMI SD scores were calculated with a growth calculator using 
WHO growth data, and the corresponding growth standard 
curves are shown in Figures 1 and 2.2 The ratio sitting height/
subischial leg length × 100 SD was calculated according to Prader 
et al. (8).
Linear relationships were assessed by Spearman rank correla-
tion analyses. p < 0.05 was considered significant.
Androstenedione was measured by Chemiluminescence 
Immunoassay on an Immulite 1000 immunoanalyzer (Siemens 
Healthcare GmbH, Erlangen, Germany) with a measuring range 
of 1.05–35.0  nmol/l and a coefficient of variation of 10.4% at 
4.1 nmol/l. Profiling of steroid hormones and urinary steroids 
was done by gas chromatography mass spectrometry (GC-MS) 
on a PolarisQ (Finnigan, Brechbühler, Schlieren, Switzerland) 
supplied with a Restek™ RTX™-1 MS column (Fischer 
Scientific, Reinach, Switzerland) according to methods reported 
by Shackleton (PMID:3525596). The urine samples were prepared 
by pre-extraction of steroids (Chromabond C18ec; Macherey-
Nagel AG, Oensingen, Switzerland), enzymatic hydrolysis with 
β-glucuronidase/arylsulfatase (Roche, Rotkreuz, Switzerland), 
extraction from the hydrolysis mixture (Chromabond C18ec), 
derivatization with methoxylamine hydrochloride and tri-
methylsilylimidazole (Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland), and gel filtration (Lipidex 5000; Perkin Elmer 
AG, Schwerzenbach, Switzerland) before analysis was done by 
GC-MS. CYP21A2 mutation analysis was performed using the 
CAH StripAssay® (ViennaLab Diagnostics, Vienna, Austria) 
covering the 11 most frequent CYP21A2 mutations: c.89C>T 
(P30L), c.290-13C>G (I2 splice), c.329_336del (Del 8bp E3), 
c.515T>A (I172N), c.[707T>A;710T>A;716T>A] (Cluster 
E6), c.841G>T (V281L), c.920_921insT (L307 frameshift), 
c.952C>T (Q318X), c.1066C>T (R356W), c.1357C>T (P453S), 
and c.1448G>C R483P. CYP21A2 copy number analysis was 
performed using the SALSA MLPA P050 CAH probemix (MRC-
Holland, Amsterdam, the Netherlands). Reference Sequence 
NM_000500.6 was used.
Both patients and their parents gave written informed consent 
to recently re-performed mutation analysis and to the publication 
of their data.
Case RepoRts
patient 1
She was born at term with a birth weight of 3210 g (−0.04 SD) and 
length of 49 cm (−0.07 SD). Pregnancy had been uneventful. She 
showed virilized genitalia Prader scale III–IV at birth. Karyotype 
was 46, XX. At the first day of life, plasma cortisol concentration 
was slightly diminished (187  nmol/l), and ACTH was elevated 
(74  pmol/l, normal values 2–11.4). Plasma 17-OHP level was 
elevated at the first (934 nmol/l) and fourth day (54 nmol/l) of 
life. A diagnosis of CAH was made, and appropriate treatment 
was begun with HC from the fourth day of life. At day 6 of life, 
she developed signs of salt-wasting (SW) and fludrocortisone 
2 www.who.int/childgrowth/standards.
FIGURe 1 | Growth curve of patient 1.
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FIGURe 2 | Growth curve of patient 2.
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taBLe 1 | Comparison of given auxological parameters between a published cohort of 38 female patients with salt-wasting (sW)–congenital adrenal 
hyperplasia (CaH) and our two patients.
H-sDs at 
2 years
H-sDs at puberty 
onset
H-sDs at final 
height (FH)
total pubertal 
growth (cm)
ΔH-sDs—FH H-sDs 
at puberty onset 
 ΔBa—Ca at puberty 
onset
SW–CAH (38 F) 
Cohort of Bonfig et al. (2)
−0.4 ± 0.2 0.03 ± 1.4 −0.8 ± 0.9 13.8 ± 7.6 −0.5 ± 0.8 0.2 ± 1.3
Patient 1 −2.9 −2.8 −1.1 29.0 1.6 −3.6
Patient 2 −2.6 −1.0 −1.8 21.0 −0.8 −2.8
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(FC) treatment was added. Under HC, FC, and salt replace-
ment, 17-OHP concentration had diminished to 53 nmol/l and 
androstenedione to 10 nmol/l at day 25 of life. Molecular analysis 
revealed a homozygous mutation c.290-13A>G (I2 splice) in the 
21-hydroxylase gene. Surgery with correction of the urogenital 
sinus and clitoroplasty was performed at 6 months of age. During 
infancy, her weight gain was normal; however, she showed decel-
erated growth: at 4 months of age, her length was already below 
the third percentile (−3.2 SD). At the age of two, her height was 
−2.9 SD, at onset of puberty −2.8 SD. She showed a normal total 
pubertal growth of 29 cm. She reached an FH of 155.5 cm (−1.1 
SD), corresponding to −1 SD below parental target height [height 
of mother: 165 cm, height of father: 173 cm; resulting familial 
target height: 162.5 cm (154–171 cm) (−0.1 SD) (Table 1)]. The 
patient shows rather short legs with SH/SILL × 100 = +2.3 SD.
Bone age (BA) was retarded during the whole follow-up 
[between chronological age 2.6 and 14.4  years, average differ-
ence between BA and chronological age (CA) (ΔBA–CA) was 
−1.9 years] (Figure 1). Thelarche (B2) started at the age of 10.9, 
with a ΔBA–CA of −3.6 years at that time, and pubarche (P2) 
started at the age of 12. Menarche occurred at the age of 14.9, 
followed by 1 year of amenorrhea. At the age of 16, polymenor-
rhea with hypomenorrhea developed. At that time, there were 
no other clinical (no acne, no hirsutism) or biochemical (no 
hyperandrogenemia, normal ratio of LH/FSH) signs of PCOS. 
Initially, progesterone replacement therapy was successful but 
had to be stopped because of subjective side effects (nausea). 
Eventually, a contraceptive pill was introduced. Delayed BA fits 
well to a history of constitutional delay of growth and develop-
ment of her mother with menarche at 15 years of age. In addition, 
she reported a tendency to anovulatory cycles over years.
The patient’s average HC supplementation dose was 16.8 mg/
m2/day from birth to 18  years of age given twice/day or for a 
limited time three times/day (Figure 1). From 0 to 2 years, her 
average dose was 20 mg/m2/day, from 2 to the onset of puberty 
at 10.9 years of age 16.3 mg/m2/day and during puberty to FH 
15.9  mg/m2/day. FC was initially 0.075  mg/day, reduced to 
0.05  mg/day at 1.5  years of age and augmented to 0.1  mg/day 
at 4.8 years of age. BMI throughout childhood and adolescence 
oscillated between +0.1 and +1 SD with a BMI of 21.7  kg/m2 
(+0.1 SD) at the age of 18. During the entire follow-up period, 
the patient remained normotensive. As known, overweight and 
hypertension can be long-term side effects of HC and FC therapy 
(9, 10).
Starting in infancy, she suffered from at least four well-
documented severe adrenal crises of weakness with apathy, 
vomiting, and hypoglycemia during the initial phase of inter-
current infectious diseases. These episodes were treated by the 
parents with immediate intramuscular injections of HC. The last 
crisis occurred at 11.5 years of age.
Laboratory results confirmed excellent adherence of the 
patient to the treatment regimen. Urinary 17-ketosteroids were 
only once in the upper normal range at 2 years of age, otherwise 
always in the low-to-mid normal range. Androstenedione was 
always normal, mostly <1 nmol/l in prepuberty and thereafter 
between 1 and 3.8 nmol/l.
patient 2
Starting in the fourth week of pregnancy, the mother received 
dexamethasone 3 × 0.5 mg daily. The diagnosis of classical CAH 
was confirmed in the fourth month of pregnancy by molecular 
genetic analysis and, thus, treatment was continued until the 
end of pregnancy. Otherwise, pregnancy was uneventful and the 
mother showed no side effects of dexamethasone therapy. The 
girl was born at term with normal female genitalia. 17-OHP was 
elevated with a value of 475 nmol/l. She developed signs of SW 
(Sodium 125  mEq/l, potassium 5.5  mEq/l) at day 6 of life and 
treatment with HC, FC, and salt was initiated.
Similar to her elder sister, she grew more slowly during the 
first 6 months of life. At 6 months of age, her length was below 
the third percentile (−2.6 SD). At 2  years of age, her height 
was −2.6 SD, at onset of puberty −1 SD. She showed a normal 
total pubertal growth of 21 cm (Table 1). She reached an FH of 
151 cm (−1.8 SD), corresponding to −1.7 SD to target height. 
Like her elder sister, she also has rather short legs with SH/
SILH × 100 = +2.4 SD.
BA was retarded until the age of 12 (between 2.9 and 12 years 
of age, ΔBA–CA was −1.5  years), thereafter, slightly advanced 
(between 12 and 13.5  years of age, ΔBA–CA was +0.7  years) 
(Figure 2). Thelarche appeared at 9.5 years of age, with a ΔBA–CA 
of −2.5 at that time and pubarche at 10.8 years. Breast develop-
ment progressed rapidly. Menarche occurred at 12.5 years of age, 
followed by regular menses.
The patient’s average HC supplementation dose was 16.8 mg/
m2/day from birth to the age of 17, given twice/day or for a limited 
time three times/day (Figure 2). From 0 to 2 years, her average 
dose was 17.9 mg/m2/day and during puberty 17.1 kg/m2/day. HC 
dose at the beginning of puberty was 14.3 mg/m2/day. FC dose 
was 0.1  mg/day throughout childhood and adolescence. BMI 
remained stable throughout childhood and puberty at +1 SD 
(P75-90) with a BMI of 21 kg/m2 (0 SD) at the age of 17. During 
the entire follow-up period, the patient remained normotensive.
taBLe 2 | Comparison of given parameters [hydrocortisone (HC)-dose and BMI] between a published cohort of seven female patients with salt-wasting 
(sW)–congenital adrenal hyperplasia (CaH) and our two patients.
HC mg/m2/day BMI sDs
0 → 2 years 2 years of 
age → p2
p2 → final 
height
0 → 2 years 2 years → p2 p2 → final height 
(FH)
SW–CAH (13 F) 
Cohort of Manoli et al. (11)
28.2 ± 7.2 14.7 ± 2.5 16.8 ± 3.6 −0.26 ± 2 1.2 ± 1.1 1 ± 1.1
0 → 2 years 2 years of 
age → B2
B2 → final 
height
at 2 years at start of puberty at FH
Patient 1 20.0 16.3 15.9 0.2 0.5 0.14
Patient 2 17.9 16.0 17.1 0.8 1.0 −0.03
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Like her sister, she suffered from adrenal crises with apathy, 
vomiting, and hypoglycemia, which were treated by her parents 
with immediate intramuscular injections of HC. During one of 
these crises at 18  months of age, after a short history of diar-
rhea and vomiting starting 2  days earlier, she was hospitalized 
in a soporific but only slightly dehydrated state. Plasma sodium 
concentration was 125  mmol/l and potassium concentration 
was 3.8 mmol/l. After administration of HC 50 mg and sodium 
chloride intravenously, she recovered rapidly and completely. The 
crisis was interpreted as SW. The last of this kind of crisis occurred 
at the age of 6.6.
Laboratory results confirmed excellent adherence to treatment 
since androstenedione concentrations always remained within 
normal limits, <1  nmol/l during childhood and early puberty 
and thereafter between 1.3 and 4.9 nmol/l.
DIsCUssIoN
The two patients described with an SW form of 21-hydroxylase 
deficiency attained a normal but rather short adult height. The 
detailed analysis of the data of the two siblings may suggest that 
constitutional genetic factors influenced FH more strongly than 
SW–CAH itself and its related treatment.
Excellent adherence to glucocorticoid and mineralocorticoid 
treatment, also during puberty, is a very important feature in our 
two patients and makes them suitable for reliable auxological 
analysis. The results of such an analysis were partly compared 
with those published in two large cohorts of females with SW–
CAH (2, 11) (Tables 1 and 2). As depicted in Table 1, heights of 
our patients were lower at 2 years of age and similar or slightly 
lower at the onset of puberty. Interestingly enough, total pubertal 
growth gain was higher in our patients. Nevertheless, their FHs 
were rather in the lower range. As depicted in the corresponding 
growth curves (Figures 1 and 2), BA was quite delayed during 
childhood in both patients. Patient 1 showed a normal onset of 
puberty at the age of 11 and menarche occurred almost 4 years 
later. However, patient 2 started puberty rather early despite 
delayed BA and menarche occurred 3 years later. Such different 
behavior may be due to different degrees of inherited predisposi-
tion to constitutional delay.
On the other hand, it may be argued that the delay in BA 
during childhood demonstrated in both siblings might be the 
consequence of glucocorticoid overtreatment.
As partly depicted in Table 2, the average HC doses in our 
patients were rather in the lower range of HC dose reported in 
large cohorts in the literature (2, 11, 12). The average HC dose 
patient 1 received from birth to 2 years, was 20 mg/m2, calculated 
including the dose of approximately 30 mg/m2 in the first 2 months 
of life (given in another center), which was promptly reduced to a 
mean dose of 16.2 mg/m2, given twice a day from the sixth month 
of life on. The average HC dose in patient 2 from birth to 2 years 
was 17.9 mg/m2, also calculated from birth on. The few specific 
data for that period of life in the literature show mostly quite more 
than 20 mg/m2/day (11). The very early growth deceleration dur-
ing the first years of life observed in both patients was followed by 
completely normal growth velocity during childhood beyond the 
first 2 years of life (+0.2 SD in patient 1 and −0.1 SD in patient 2), 
which further supports the notion of constitutional delay.
Of note, a significant correlation was found between HC 
dose and growth velocity SD during childhood and adolescence 
(r2 = 0.27, p = 0.034 in patient 1; r2 = 0.52, p = 0.0023 in patient 
2). Such correlation may be interpreted differently. Either as a 
good match between dose adjustment and growth velocity or 
it may reflect a constant overtreatment, which prevented catch 
up growth. However, the latter interpretation is not compatible 
with the good pubertal growth spurt observed in both patients 
(Table 1) (2).
Other important arguments against a glucocorticoid over-
treatment are the low-to-normal blood pressure and the normal 
BMI observed in both siblings. FC dose could be maintained in 
our patients at ≤0.1  mg/day, which was surely convenient for 
blood pressure in the long term (9).
The origin of the slightly altered body proportions in both 
girls with rather short legs remains unclear. Even though 
both parents showed normal body proportions, familiarity 
cannot be excluded since both grandmothers and paternal 
grandaunts were of rather short stature (150–155  cm). 
Unfortunately, body proportions of these relatives could 
not be investigated. However, in the complete absence of 
any clinical signs of iatrogenic glucocorticoid excess, HC 
overtreatment seems an unlikely cause for this observation. 
Nevertheless, selective sensitivity of long bones to the effect 
of glucocorticoids in the first years of life cannot be definitely 
excluded.
During childhood, both siblings developed recurrent episodes 
of SW. The underlying homozygous mutation c.290-13A>G (I2 
splice) in the 21-hydroxylase gene was previously described to 
7Lang-Muritano et al. Siblings with CAH: Auxological Analysis
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result either in SW–CAH (78.6%) or in a simple virilizing form 
(approximately 20%) (13, 14). Apparently, our patient seems to 
belong to the group with the SW form.
Polycystic ovary syndrome is more common in females with 
CAH (3). In this regard, the chronically anovulatory cycle pattern 
observed in patient 1 may suggest PCOS. In fact, no other clinical 
and laboratory signs for such disease were detected, and adher-
ence to CAH treatment was very good. Given the mother’s history 
of anovulatory cycles over years, the cycle abnormalities observed 
in patient 1 may be rather due to familial factors.
In the second sibling, masculinization could be completely 
prevented by early prenatal dexamethasone treatment of the 
mother. Nevertheless, the degree of the 21-hydroxylase defect 
seems to be as severe as in the older sister given the fact that 
the younger sister developed signs of SW at the sixth day of life 
and suffered several times from adrenal crises during intercurrent 
illnesses. No apparent side effects of the prenatal dexamethasone 
treatment were present neither in the patient nor in the mother, 
as was previously reported for other cases of prenatal treatment in 
the literature (15). In particular, the school performance of both 
siblings is similar and high.
In conclusion, two siblings with the same genetic form of 
SW-21-hydroxylase deficiency and excellent compliance to 
glucocorticoid and mineralocorticoid supplementation showed 
different growth and menstrual cycle patterns, suggesting that 
constitutional elements strongly influence the outcome, in addi-
tion to the disease-specific factors and its related treatment.
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